Dewey Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -0.60%
- Profit Growth -0.29%
- Ebitda -4.10%
- Net Worth 15.01%
- Total Assets -2.22%
About Dewey Pharmaceuticals
Dewey Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 December 2019 (Five years and two months 15 days old ). Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Hrishikesh Hazarika and Tanaya Kakaty serve as directors at the Company.
Company Details
- Location
Kamrup, Assam, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230AS2019PTC019730
- Company No.
019730
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Dec 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Dewey Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hrishikesh Hazarika  | Director | 10-Dec-2019 | Current |
| Tanaya Kakaty | Director | 10-Dec-2019 | Current |
Financial Performance of Dewey Pharmaceuticals.
Dewey Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.6% decrease. The company also saw a slight decrease in profitability, with a 0.29% decrease in profit. The company's net worth Soared by an impressive increase of 15.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dewey Pharmaceuticals?
In 2023, Dewey Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hhht Healthcare Private LimitedHrishikesh Hazarika and Tanaya Kakaty are mutual person
- Cosmo Magnum (Opc) Private Limited
Hrishikesh Hazarika is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dewey Pharmaceuticals?
Unlock and access historical data on people associated with Dewey Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dewey Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dewey Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.